TCGA-E9-A244-01A-11R-A169-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.490
- MYC_TARGETS_V2+0.480
- E2F_TARGETS+0.420
- MTORC1_SIGNALING+0.370
- CHOLESTEROL_HOMEOSTASIS+0.360
- G2M_CHECKPOINT+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- GLYCOLYSIS+0.210
- APICAL_JUNCTION+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.340
- ESTROGEN_RESPONSE_EARLY-0.190
- BILE_ACID_METABOLISM-0.180
- XENOBIOTIC_METABOLISM-0.160
- ESTROGEN_RESPONSE_LATE-0.150
- PANCREAS_BETA_CELLS-0.150
- PEROXISOME-0.150
- COMPLEMENT-0.120
- INFLAMMATORY_RESPONSE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AE6Y-TTM1-A-1-1-R-A742-41 | — | E | 0.850 |
| 2 | TCGA-B6-A0RE-01A-11R-A056-07 | — | E | 0.819 |
| 3 | TCGA-A2-A0T0-01A-22R-A084-07 | — | E | 0.814 |
| 4 | TCGA-43-6770-01A-11R-1820-07 | — | cohortSQ2 | 0.806 |
| 5 | R156 | — | — | 0.801 |
| 6 | SRR5088878 | — | — | 0.796 |
| 7 | SRR35579803 | — | E | 0.794 |
| 8 | TCGA-AN-A0G0-01A-11R-A034-07 | — | E | 0.790 |
| 9 | TCGA-B6-A0RU-01A-11R-A084-07 | — | E | 0.788 |
| 10 | TCGA-AN-A0FJ-01A-11R-A00Z-07 | — | E | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |